×
0 0 0 0 0 -0.121058823529412 -0.0480392156862745 -0.0490196078431372
Stockreport

Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc (ADVM)  More Company Research Source: GlobeNewswire
Last adverum biotechnologies, inc earnings: 3/6 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF - Clinical Hold until Additional CMC Information is Reviewed by FDA -- Independent DMC Review of Safety Data from First Cohort of Six Patients with No SAEs or DLTs -- Adverum Plans to Present 24-Week Data from First Cohort of Patients at Scientific Meeting in 2H19 - MENLO PARK, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided a program update on ADVM-022, a novel, single-administration gene therapy being evaluated in the OPTIC Phase 1 clinical trial in patients with wet age-related macular degeneration (wet AMD). The Company has completed enrollment and dosing of patients (n=6) in the first cohort in the OPTIC trial. The independent data monitoring committee (DMC) determined that enrollment and dosing of patients in the second cohort could proceed. This was based on a review of the preliminary safety data from the first coh [Read more]

IMPACT SNAPSHOT EVENT TIME: ADVM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ADVM alerts
from News Quantified
Opt-in for
ADVM alerts

from News Quantified
Opt-in for
ADVM alerts

from News Quantified